Vinge is advising Medivir AB (publ) in connection with a rights issue which will provide Medivir with issue proceeds amounting to a maximum of SEK 170 million, as well as with an over-allotment option by way of a directed share issue of a maximum of approximately SEK 25 million.
Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients.
Medivir is listed on Nasdaq Stockholm, Small Cap.
Vinge’s team mainly consisted of Dain Hård Nevonen, Amanda Knutsson, Julia Hirschberg and Olof Löfvenberg.
